Related Experiment Video
Updated: Sep 14, 2025

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
Published on: August 15, 2020
Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human
Mrutyunjaya Panda1, Maria Fakitsa2, Maria Markaki3
1Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion 70013 Crete, Greece; Department of Medicine, University of Verona, Verona 37134, Italy; Faculty of Pharmacy, University of Lisbon, Lisbon 1649-003, Portugal.
Abstract:
An increase in the aging population is accompanied by increased susceptibility to age-associated neurodegeneration, with currently no cure. Despite the diversity of symptoms and etiologies, neurodegenerative disorders share mechanistic commonalities and many pathophysiological features. These include disruptions in circadian rhythms that affect neuronal physiology. Systematic investigations in several animal models have advanced our understanding of the molecular processes that link circadian rhythms and neurodegenerative disease states. These models have also been used to screen and validate promising chronotherapeutic drug candidates that target the circadian clock to ameliorate neurodegeneration. With the emergence of robust and reliable methodologies to measure daily rhythms, the nematode model Caenorhabditis elegans has become a versatile tool for high throughput chronotherapeutic drug screening against neurodegenerative disorders. In this review, we discuss the unique features and advantages of C. elegans as an enabling platform for chronotherapeutic drug discovery, towards the development of innovative strategies for the treatment of human neurodegenerative conditions.

